A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of Nexvax2 in Patients With Celiac Disease

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of Nexvax2 in Patients With Celiac Disease

Completed
Phase of Trial: Phase I

Latest Information Update: 12 May 2017

At a glance

  • Drugs HLA DQ2 peptide vaccine (Primary)
  • Indications Coeliac disease
  • Focus Adverse reactions
  • Sponsors ImmusanT
  • Most Recent Events

    • 12 May 2017 Results from this and other trial (see profile 239677) published in an ImmusanT Media Release
    • 11 May 2017 Results from this and other trial (see profile 239677) published in The Lancet Gastroenterology and Hepatology
    • 22 Mar 2017 Status changed to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top